PAI Pharma (PAI), a portfolio company of Olympus Partners and a US-based developer, manufacturer, and marketer of oral liquid medicines and Ready-To-Use (RTU) sterile injectables, announced on Thursday the acquisition of Nexus Pharmaceuticals, LLC, an Illinois-based pharmaceutical company specialising in the development and commercialisation of injectable medicines used in critical care, oncology, and other hospital settings.

PAI says that the acquisition marks another significant step in its strategy to build a broader portfolio of essential medicines and expand its presence in the hospital and sterile injectable markets.

Nexus brings an established commercial portfolio of over 20 hospital injectable products, customer relationships, and expertise in developing and commercialising critical therapies. Combined with PAI's experience in Ready-to-Dose oral liquid medicines and growing sterile injectable business, including the recent acquisition of Nivagen and its aseptic manufacturing capabilities in Sacramento, the acquisition is claimed to strengthen PAI's ability to serve hospitals and healthcare providers with a broader range of high-quality pharmaceutical products.